US FDA Has Soured On Abuse Deterrent Labeling Even Outside Of Opioids, Stimulant Docs Suggest

 
• By Sarah Karlin-Smith
  
Steep grades and curves, road sign, dangerous road
Arbor faces a difficult road to advisory committee and FDA sign-off for its reformulated ADHD treatment • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers